Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects

Abstract

Importance of the field: AIDS, a disease caused by human immunodeficiency virus, was called ‘plague of the twentieth century’. 3′-Azido-3′-deoxythymidine (AZT), the first compound approved for the treatment of HIV, is still a mandatory component of treatment schemes. However, its toxicity stimulated a search for new agents.

Areas covered in this review: This review presents the history and current state of the design of AZT prodrugs based on its phosphonate derivatives.

What the reader will gain: Although every effort was made to include as many AZT structures bearing phosphonate residues and demonstrate the variety they offer, we also concentrated on the studies performed in our laboratory. Special attention was also paid to AZT 5′-H-phosphonate (phosphazide, Nikavir^®) approved in the Russian Federation as a drug for the prevention and treatment of HIV infection.

Take home message: The prodrug strategy applied to AZT phosphonate derivatives enriched chemistry, biology and medicine not only with new knowledge, methods and structures, but also with a new anti-HIV drug Nikavir. Currently, study of another phosphonate, AZT 5′-aminocarbonylphosphonate, is underway. Slow release of AZT following oral administration and penetration into cells, decreased toxicity and the lack of cumulative properties make the compounds of this group promising as extended-release forms of AZT.

Keywords::

• anti-HIV
• AZT
• phosphazide
• phosphonates
• prodrugs

Acknowledgements

The authors thank K Seley-Radtke of the University of Maryland, Baltimore County, USA, for her assistance in the preparation of this manuscript.

Notes

This box summarizes key points contained in the article.